The prevalence of obesity in the USA has been increasing over the past few decades, and despite the availability of approved anti-obesity medications (AOMs), people with obesity may not be accessing or receiving treatment at levels consistent with the disease prevalence
[DOI] [PMC free article] [PubMed] [Google Scholar] 112.Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzn S, et al
These treatments do not create dramatic overnight changes, but they consistently reshape appetite signals, stabilize blood sugar, reduce cravings, and support sustainable fat loss
Furthermore, the finding that symptom screening did not correlate with RGV suggests that current recommendations to rely on UGI symptom checks are likely insufficient
Characterized by cell injury and inflammatory cell infiltration, NASH is regarded as a more aggressive form of NAFLD possibly progressing to cirrhosis and hepatocellular carcinoma with limited treatment options (118) and with a history of NASH, the possibility of suffering liver and cardiovascular diseases is greatly increased (119)
